iX Biopharma Ltd, a specialty pharmaceutical and nutraceutical company headquartered in Singapore, has been making significant strides in the healthcare sector. The company, listed on the Singapore Exchange, focuses on developing, manufacturing, and commercializing therapies for acute and breakthrough pain, among other health conditions, across Australia, Singapore, and Malaysia. With a market capitalization of 369,830,016 SGD, iX Biopharma operates through three primary segments: Specialty Pharmaceutical, Chemical Analysis, and Nutraceutical.
The company’s product portfolio includes several innovative therapies. Their lead product candidate, Wafermine, is a sublingual ketamine oral wafer currently in phase 2 clinical trials for managing moderate to severe pain. Additionally, iX Biopharma offers BnoX, a sublingual buprenorphine wafer designed for similar pain management applications. For male erectile dysfunction, the company has developed Wafesil, a sublingual sildenafil wafer, and Silcap, both aimed at providing effective treatment options.
Beyond pharmaceuticals, iX Biopharma is actively involved in the nutraceutical market. The company promotes and markets nutritional and supplement products through pharmacies and online platforms. They are also engaged in the development and commercialization of nutraceutical products, expanding their reach in the health and wellness sector.
In addition to their pharmaceutical and nutraceutical endeavors, iX Biopharma provides laboratory services, further diversifying their offerings within the healthcare industry. Founded in 2008, the company has established a strong presence in the region, leveraging its expertise to address various health needs.
Despite a challenging financial outlook, as indicated by a price-to-earnings ratio of -51.649, iX Biopharma continues to focus on innovation and growth. The company’s close price as of May 21, 2026, was 0.345 SGD, reflecting recent market conditions. Over the past year, the stock has experienced significant volatility, with a 52-week high of 0.46 SGD on April 14, 2026, and a low of 0.015 SGD on June 30, 2025.
For more information, iX Biopharma maintains an online presence through their website, www.ixbiopharma.com , where stakeholders can access detailed insights into their operations and product developments. As the company continues to navigate the complexities of the healthcare market, its commitment to innovation and patient care remains a cornerstone of its strategy.
